Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa

• Published in: Frontiers in cellular and infection microbiology Vol. 13; p. 1023948
• Main Authors: Kang, Yixin, Xie, Lu, Yang, Jiyong, Cui, Junchang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 28.06.2023
• Subjects: 173 aztreonam-avibactam; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Aztreonam - pharmacology; beta-Lactamases; ceftazidime-avibactam; Cellular and Infection Microbiology; Drug Combinations; extensively drug-resistant Pseudomonas aeruginosa; Humans; Microbial Sensitivity Tests; pan drug-resistant Pseudomonas aeruginosa; Pharmaceutical Preparations; Pseudomonas aeruginosa; Pseudomonas Infections - drug therapy; Respiratory Tract Infections - drug therapy; Sepsis - drug therapy; whole-genome sequencing; extensively drug-resistant Pseudomonas aeruginosa; ceftazidime-avibactam; pan drug-resistant Pseudomonas aeruginosa; whole-genome sequencing; 173 aztreonam-avibactam

To evaluate the efficacy of ceftazidime-avibactam (CZA) and aztreonam-avibactam (AZA) against bloodstream infections (BSIs) or lower respiratory tract infections (LRTIs) - caused by extensive drug-resistant or pan drug-resistant (XDR/PDR) The two-fold dilution method was used to determine the minimu...